{"id":"NCT02814565","sponsor":"Takeda","briefTitle":"Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin","officialTitle":"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial to Study the Efficacy and Safety of Cyclobenzaprine HCl Extended Release (CER) 15 mg in Subjects With Acute Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-12","primaryCompletion":"2017-02-10","completion":"2017-03-14","firstPosted":"2016-06-27","resultsPosted":"2019-04-08","lastUpdate":"2019-04-08"},"enrollment":180,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Neck Pain","Back Pain","Spasm"],"interventions":[{"type":"DRUG","name":"Cyclobenzaprine HCl","otherNames":["Myorix®","AMRIX®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Cyclobenzaprine HCl 15 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to assess the effect of cyclobenzaprine hydrochloride (HCl) extended release (CER) 15 mg capsule once daily in participants with muscle spasms associated with acute painful musculoskeletal conditions.","primaryOutcome":{"measure":"Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Day 3 of Treatment","timeFrame":"Day 3","effectByArm":[{"arm":"Cyclobenzaprine HCl 15 mg","deltaMin":20,"sd":null},{"arm":"Placebo","deltaMin":28.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6179"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":90},"commonTop":["Somnolence","Dry mouth","Flatulence","Poor quality sleep","Influenza"]}}